Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Inactivated H7N9 Vaccine in H7N7-Primed Adults
NCT02586792Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2016
- Primary completion
- Dec 2016
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of monovalent inactivated influenza A/H7N9 virus vaccine in Influenza A Virus H7N9 Infection, sponsored by National Institute of Allergy and Infectious Diseases. Started Jan 2016; status: completed.
02
Drugs
monovalent inactivated influenza A/H7N9 virus vaccine
03
Conditions
Influenza A Virus H7N9 Infection
Beyond the preview
Go deeper on NCT02586792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02586792.